35,410 Shares in Incyte Corporation $INCY Acquired by Corient Private Wealth LP

Posted by Brenda Bartman on Sep 1st, 2026

Corient Private Wealth LP bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) during the second quarter, HoldingsChannel reports. The institutional investor bought 35,410 shares of the biopharmaceutical company’s stock, valued at approximately $4,014,000.

Other large investors have also recently bought and sold shares of the company. Fiduciary Financial Advisors purchased a new stake in shares of Incyte in the second quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in Incyte during the 4th quarter worth about $28,000. Smithfield Trust Co raised its stake in Incyte by 135.0% in the 4th quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 162 shares during the last quarter. MUFG Securities EMEA plc acquired a new position in Incyte in the 2nd quarter valued at about $32,000. Finally, CYBER HORNET ETFs LLC purchased a new position in Incyte in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Price Performance

INCY opened at $123.22 on Tuesday. Incyte Corporation has a 12 month low of $81.09 and a 12 month high of $132.60. The business has a 50-day moving average of $119.38 and a two-hundred day moving average of $105.15. The stock has a market capitalization of $24.98 billion, a price-to-earnings ratio of 15.70, a price-to-earnings-growth ratio of 3.91 and a beta of 0.76.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.94. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period in the prior year, the firm posted $1.57 EPS. The company’s revenue was up 37.7% on a year-over-year basis. Equities research analysts anticipate that Incyte Corporation will post 2.64 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Mizuho raised their price target on shares of Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Citigroup reissued a “buy” rating on shares of Incyte in a research report on Monday, August 3rd. Piper Sandler upped their price objective on shares of Incyte from $110.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. BMO Capital Markets raised their target price on shares of Incyte from $112.00 to $130.00 and gave the stock a “market perform” rating in a research report on Wednesday, July 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $150.00 price target on shares of Incyte in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $123.10.

Read Our Latest Research Report on Incyte

Insider Activity at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 10,801 shares of Incyte stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total value of $1,356,173.56. Following the transaction, the insider owned 183,200 shares in the company, valued at $23,002,592. This trade represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick A. Mayes sold 41,899 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the sale, the executive vice president directly owned 61,441 shares of the company’s stock, valued at $7,339,741.86. This represents a 40.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 16.20% of the company’s stock.

Incyte Profile

(Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.